Why did the WHO recommend not to use the drug that Trump was treated with from Corona?

A committee affiliated with the World Health Organization ‘WHO’ recommended not to use the drug “Remdesivir”, which was used in the treatment of US President Donald Trump after being infected with the new Coronavirus, and the vaccine that the company “AstraZeneca” and “The University of Oxford” is working on showed of Oxford) showed a strong immune response in the elderly, while the vaccine company “Pfizer” and “BioNTech” for drugs achieved an efficacy of 94% among people over the age of 65 years.

We start with the drug that was used to treat Trump, as a committee of the World Health Organization recommended today, Friday, that the drug remdesivir, produced by Gilead Sciences, should not be used in the treatment of Covid-19 patients in hospitals, regardless of the degree of their illness. There is no evidence that it improves survival chances or reduces the need for ventilators, and Gilead Sciences manufactures the drug under the name “Veklury”.

Remdesivir was one of the drugs that doctors used to treat Trump after being infected with the new Coronavirus that causes Covid-19 disease. It has been proven in previous studies that it shortened the recovery time, and more than 50 countries approved it as a treatment for Corona or authorized its use for this purpose.

“The committee did not find sufficient evidence that remdesivir improved patient outcomes, such as reduced death rate, decreased need for ventilation, and reduced time for clinical improvement, among other things,” the committee said in its guidelines.

These guidelines represent a setback for the drug, which attracted the world’s attention as a possible treatment for Covid-19 disease in the summer after early trials showed some promising results.

This anti-viral drug is currently one of only two drugs approved for use in treating Covid-19 patients worldwide. But a large experiment led by the World Health Organization last month, known as the Solidarity Experience, showed that it did not affect death rates within 28 days of positive tests or on the period of stay in hospital.


Gilead Sciences questioned the results of the solidarity experiment. They said in a statement that the drug “has been recognized as a standard for inpatient care with Covid-19 virus in the guidelines of many trusted national organizations.”

“We are disappointed that the WHO guidelines ignore this evidence at a time when cases are increasing dramatically around the world, and doctors rely on our drug as the first approved antiviral treatment only for Covid-19 patients,” she added.

The WHO Guidelines Development Group said its recommendation was based on a review of the evidence, which included data from 4 international randomized trials involving more than 7,000 hospitalized patients with COVID-19.

Last October, the United States approved the drug “remdesivir” to treat people infected with the Coronavirus.

Remdesivir is an experimental antiviral drug that Gilead Sciences initially developed to treat the 2015 Ebola virus.

Initially, it showed promising results in studies to treat Ebola and was later introduced in the Democratic Republic of the Congo. But it ultimately failed as an effective treatment.

Remdesivir mimics adenosine, one of the four building blocks of RNA. According to AFP, when the virus incorporates remdesivir into its genome instead of adenosine, it becomes unable to replicate.

Oxford vaccine is promising with older adults

Data published Thursday showed that the vaccine, which AstraZeneca and the University of Oxford are working on, has achieved a strong immune response in the elderly. Researchers expect to publish the results of the final stage of tests by Christmas.

The data indicate that the vaccine has provided those over the age of 70, who are the most vulnerable group to disease and death from Covid-19, strong immunity from the disease.

Maheshi Ramasamy, consultant and co-head of the research team at the Oxford Vaccine Group, said he hoped the vaccine would help protect some of the most vulnerable groups. But he stressed that more research is needed before this can be confirmed.

The director of the Oxford Vaccine Group, Andrew Christmas, will know the results of these experiments now by Christmas. It is too early to know how successful the vaccine will be in preventing Covid-19 infections.

The Oxford / AstraZeneca vaccine was among the most prominent vaccines developed as part of international efforts to combat the Coronavirus.

However, Pfizer and BioNtech Pharmaceuticals, and Moderna have made progress in the last ten days, and data on last-phase trials of two vaccines have shown that their efficacy exceeds 90%.

On Monday, Moderna released preliminary data on its vaccine, showing its effectiveness of 94.5%.

The Pfizer BioNtech vaccine is effective in people over the age of 65

Next month, Pfizer and BioNtech seek to obtain approval from American and European regulatory agencies for the emergency use of their Covid-19 vaccine, after the results of the final trials showed that the vaccine’s success rate is 95% with no serious side effects.

The effectiveness of the vaccine was found to be stable in different age groups and ethnicities. This is a promising sign, given that the disease affected the elderly and certain groups, including black-skinned people, more than others.

And it was found that the Pfizer BioNtech vaccine has achieved effectiveness of 94% among people over the age of 65, which experts described as very important at a time when the virus is spreading around the world with record infections.

“This is the evidence we needed to ensure that people most at risk were protected,” said Andrew Hill, a visiting researcher in the pharmacology department at the University of Liverpool.

Source : Agencies